Clinical trials: Pre-Term
Erectile Dysfunction, Premature (Early) Ejaculation
Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
The objective of this clinical trial is to evaluate the effectiveness of pelvic floor therapy for the management of erectile dysfunction and premature ejaculation in patients with erectile dysfunction and premature ejaculation.
- Conditions
- Erectile Dysfunction, Premature (Early) Ejaculation, Premature Ejaculation, Pelvic Floor; Weak
- Trial name
- NCT06425211
- Testing
- Therapeutic exercises, Perineal electromyographic biofeedback, Electrical stimulation
- Where
- Colombia
- Volunteers
- 66 people
- Sponsor
- Boston Medical Group
Premature Ejaculation
A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation
The purpose of this study is to evaluate the safety and efficacy of on-demand therapy with CDFR0812-15/25mg and CDFR0812-15/50mg compared to on-demand therapy with single-drug administration of Clomipramine HCl 15mg in Korean…
- Trial name
- NCT02571101
- Testing
- CDFR0812-15/25mg, CDFR0812-15/50mg, Condencia
- Where
- 9 sites in South Korea
- Volunteers
- 297 people
- Sponsor
- CTC Bio, Inc.
Ventricular Arrythmia, Ventricular Tachycardia
VIVO European Observational Registry
A multi-center, observational registry conducted in Europe and the UK to prospectively review VIVO in a clinical setting in 125 patients.
- Conditions
- Ventricular Arrythmia, Ventricular Tachycardia, Premature Ventricular Contraction
- Trial name
- NCT04990089
- Testing
- VIVO
- Where
- 8 sites in Ireland, Italy and 3 more
- Volunteers
- 125 people
- Sponsor
- Catheter Precision. Inc.
Eosinophilic Asthma
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by…
- Trial name
- NCT01290887
- Testing
- Reslizumab
- Where
- 219 sites in United States, Argentina and 29 more
- Volunteers
- 1,052 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Anesthesia
Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age
The primary objective of this study is to characterize the safety, and efficacy of Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a continuous IV infusion in preterm subjects, ages ≥ 28 weeks…
- Trial name
- NCT01508455
- Testing
- Dexmedetomidine, Midazolam, Fentanyl
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer